History
Following the thorough validation of our novel technology platform (proof of concept in several vaccine programs) and the establishment of development capabilities, we are currently advancing the development of new products.
More about us
02/2024
“Similar for All” development integrated
07/2023
Company growth phase initialised
Download (PDF)
06/2023
“Same for All“ manufacturing established
09/2022
Feasibility of production scale up
02/2022
10/2021
03/2021
Generation of protective maternal antibodies
07/2018
Move to own facility
04/2018
03/2018
Patents transferred from university to Verovaccines
12/2017
Seed investment round
12/2017
Filing multivalency patent
07/2017
Foundation Verovaccines GmbH
12/2014
Hugo Junkers prize
04/2014
Dr. Hennemann joins team
2009
Start research on technology
